Based on the GO enrichment analysis, we speculate that the inhibition of renal cell carcinoma by Resibufogenin may be achieved through the modulation of molecular functions such as protein kinase activity, protein tyrosine kinase activity, phosphatase binding, and phosphorylation biological processes. This evidence concerns the gene WEE1 and renal cell carcinoma.